​

Lyra Therapeutics (LYRA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

LYRA Stock Forecast

Lyra Therapeutics (LYRA) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $0.50, with a high of $0.50 and a low of $0.50. This represents a 354.55% increase from the last price of $0.11.

- $1 $2 $3 $4 $5 $6 $7 High: $0.5 Avg: $0.5 Low: $0.5 Last Closed Price: $0.11

LYRA Stock Rating

Lyra Therapeutics stock's rating consensus is Hold, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 2 Buy (40.00%), 3 Hold (60.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 5 0 3 2 Strong Sell Sell Hold Buy Strong Buy

LYRA Price Target Upside V Benchmarks

TypeNameUpside
StockLyra Therapeutics354.55%
SectorHealthcare Stocks 35.46%
IndustryBiotech Stocks 87.81%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$0.50
Last Closing Price$0.11$0.11$0.11
Upside/Downside--354.55%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25--4--4
Mar, 25--4--4
Feb, 25--4--4
Jan, 25-14--5
Dec, 24-14--5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 07, 2024Dennis DingJefferies$0.50$0.52-3.85%354.55%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 15, 2024H.C. WainwrightNeutralNeutralhold
Jun 20, 2024H.C. WainwrightUnderperformUnderperformhold
May 07, 2024JefferiesBuyBuyhold
May 07, 2024JefferiesHolddowngrade
May 06, 2024BTIGBuyNeutraldowngrade
May 06, 2024BTIGBuyReducedowngrade
May 06, 2024William BlairMarket Performdowngrade
May 02, 2024Bank of America SecuritiesBuyBuyhold
Feb 07, 2023BTIGBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.27$-1.83$-1.26$-1.43----
Avg Forecast$-3.12$-1.78$-1.31$-1.33$-0.69$-0.79$-0.59$-0.22
High Forecast$-1.48$-1.26$-1.23$-1.32$-0.43$-0.74$-0.34$-0.13
Low Forecast$-4.80$-2.26$-1.37$-1.34$-1.03$-0.84$-0.83$-0.31
Surprise %4.81%2.81%-3.82%7.52%----

Revenue Forecast

$0 $20M $40M $60M $80M $100M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$285.00K$1.36M$1.56M$1.53M----
Avg Forecast$1.00M$4.19M$1.74M$1.52M$977.00K$6.06M$35.45M$73.60M
High Forecast$1.42M$5.06M$1.94M$1.64M$1.28M$7.96M$46.59M$96.71M
Low Forecast$597.80K$3.26M$1.38M$1.36M$662.10K$4.10M$24.03M$49.87M
Surprise %-71.63%-67.51%-10.41%0.69%----

Net Income Forecast

$-250M $-200M $-150M $-100M $-50M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-42.41M$-55.28M$-62.68M$-93.44M----
Avg Forecast$-155.31M$-88.67M$-62.68M$-66.12M$-36.27M$-39.13M$-29.23M$-10.96M
High Forecast$-73.54M$-62.95M$-61.27M$-65.64M$-21.41M$-36.63M$-17.07M$-6.37M
Low Forecast$-238.90M$-112.38M$-68.08M$-66.59M$-51.14M$-41.64M$-41.38M$-15.43M
Surprise %-72.69%-37.66%-41.32%----

LYRA Forecast FAQ

Is Lyra Therapeutics stock a buy?

Lyra Therapeutics stock has a consensus rating of Hold, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 2 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Lyra Therapeutics is a neutral investment for most analysts.

What is Lyra Therapeutics's price target?

Lyra Therapeutics's price target, set by 5 Wall Street analysts, averages $0.5 over the next 12 months. The price target range spans from $0.5 at the low end to $0.5 at the high end, suggesting a potential 354.55% change from the previous closing price of $0.11.

How does Lyra Therapeutics stock forecast compare to its benchmarks?

Lyra Therapeutics's stock forecast shows a 354.55% upside, outperforming the average forecast for the healthcare stocks sector (35.46%) and outperforming the biotech stocks industry (87.81%).

What is the breakdown of analyst ratings for Lyra Therapeutics over the past three months?

  • April 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.

What is Lyra Therapeutics’s EPS forecast?

Lyra Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.69, marking a -51.75% decrease from the reported $-1.43 in 2024. Estimates for the following years are $-0.79 in 2026, $-0.59 in 2027, and $-0.22 in 2028.

What is Lyra Therapeutics’s revenue forecast?

Lyra Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $977K, reflecting a -36.31% decrease from the reported $1.53M in 2024. The forecast for 2026 is $6.06M, followed by $35.45M for 2027, and $73.6M for 2028.

What is Lyra Therapeutics’s net income forecast?

Lyra Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-36.273M, representing a -61.18% decrease from the reported $-93.435M in 2024. Projections indicate $-39.134M in 2026, $-29.227M in 2027, and $-10.957M in 2028.